Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bone, Inflammation, Gut and Renal Biomarkers in Antiretroviral-Naive HIV-1 Positive Subjects Starting ART
2018-001358-84Phase 4Active
- Sponsor
- CHU Saint-Etienne
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rilpivirine, emtricitabine, raltegravir, lamivudine, ritonavir and 6 more in human immunodeficiency virus infection (HIV), sponsored by CHU Saint-Etienne. Primary endpoint: Change in fecal microbial alpha-diversity. Started Apr 2018; status: active.
02
Drugs
rilpivirineemtricitabineraltegravirlamivudineritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2018-001358-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001358-84.